vs
Apellis Pharmaceuticals, Inc.（APLS）与ETHAN ALLEN INTERIORS INC（ETD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ETHAN ALLEN INTERIORS INC的1.5倍（$199.9M vs $135.8M），ETHAN ALLEN INTERIORS INC净利率更高（4.4% vs -29.5%，领先33.9%），ETHAN ALLEN INTERIORS INC同比增速更快（-4.8% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -10.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
伊森艾伦内饰公司是美国家居家具制造商与零售商，公司注册于特拉华州，总部行政办公室位于康涅狄格州丹伯里。截至2023年6月30日，该公司年度净销售额达7.914亿美元。
APLS vs ETD — 直观对比
营收规模更大
APLS
是对方的1.5倍
$135.8M
营收增速更快
ETD
高出1.1%
-5.9%
净利率更高
ETD
高出33.9%
-29.5%
两年增速更快
APLS
近两年复合增速
-10.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $135.8M |
| 净利润 | $-59.0M | $5.9M |
| 毛利率 | — | 59.4% |
| 营业利润率 | -25.6% | 4.8% |
| 净利率 | -29.5% | 4.4% |
| 营收同比 | -5.9% | -4.8% |
| 净利润同比 | -62.2% | -38.2% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSETD
| Q1 26 | — | $135.8M | ||
| Q4 25 | $199.9M | $149.9M | ||
| Q3 25 | $458.6M | $147.0M | ||
| Q2 25 | $178.5M | $160.4M | ||
| Q1 25 | $166.8M | $142.7M | ||
| Q4 24 | $212.5M | $157.3M | ||
| Q3 24 | $196.8M | $154.3M | ||
| Q2 24 | $199.7M | $168.6M |
净利润APLSETD
| Q1 26 | — | $5.9M | ||
| Q4 25 | $-59.0M | $11.7M | ||
| Q3 25 | $215.7M | $10.5M | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | $9.6M | ||
| Q4 24 | $-36.4M | $15.0M | ||
| Q3 24 | $-57.4M | $14.7M | ||
| Q2 24 | $-37.7M | $18.5M |
毛利率APLSETD
| Q1 26 | — | 59.4% | ||
| Q4 25 | — | 60.9% | ||
| Q3 25 | — | 61.4% | ||
| Q2 25 | — | 59.9% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 60.8% |
营业利润率APLSETD
| Q1 26 | — | 4.8% | ||
| Q4 25 | -25.6% | 9.5% | ||
| Q3 25 | 48.7% | 6.8% | ||
| Q2 25 | -18.6% | 9.5% | ||
| Q1 25 | -50.0% | 7.7% | ||
| Q4 24 | -12.3% | 11.5% | ||
| Q3 24 | -24.0% | 11.4% | ||
| Q2 24 | -14.7% | 13.4% |
净利率APLSETD
| Q1 26 | — | 4.4% | ||
| Q4 25 | -29.5% | 7.8% | ||
| Q3 25 | 47.0% | 7.1% | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | 6.7% | ||
| Q4 24 | -17.1% | 9.5% | ||
| Q3 24 | -29.2% | 9.5% | ||
| Q2 24 | -18.9% | 11.0% |
每股收益（稀释后）APLSETD
| Q1 26 | — | $0.23 | ||
| Q4 25 | $-0.40 | $0.46 | ||
| Q3 25 | $1.67 | $0.41 | ||
| Q2 25 | $-0.33 | $0.48 | ||
| Q1 25 | $-0.74 | $0.37 | ||
| Q4 24 | $-0.30 | $0.59 | ||
| Q3 24 | $-0.46 | $0.57 | ||
| Q2 24 | $-0.30 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $66.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $473.7M |
| 总资产 | $1.1B | $723.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSETD
| Q1 26 | — | $66.6M | ||
| Q4 25 | $466.2M | $139.3M | ||
| Q3 25 | $479.2M | $123.6M | ||
| Q2 25 | $370.0M | $136.1M | ||
| Q1 25 | $358.4M | $172.9M | ||
| Q4 24 | $411.3M | $139.1M | ||
| Q3 24 | $396.9M | $135.9M | ||
| Q2 24 | $360.1M | $161.0M |
股东权益APLSETD
| Q1 26 | — | $473.7M | ||
| Q4 25 | $370.1M | $478.2M | ||
| Q3 25 | $401.2M | $475.5M | ||
| Q2 25 | $156.3M | $482.4M | ||
| Q1 25 | $164.2M | $479.2M | ||
| Q4 24 | $228.5M | $478.8M | ||
| Q3 24 | $237.1M | $474.7M | ||
| Q2 24 | $264.3M | $483.0M |
总资产APLSETD
| Q1 26 | — | $723.3M | ||
| Q4 25 | $1.1B | $714.8M | ||
| Q3 25 | $1.1B | $737.1M | ||
| Q2 25 | $821.4M | $737.1M | ||
| Q1 25 | $807.3M | $738.7M | ||
| Q4 24 | $885.1M | $732.6M | ||
| Q3 24 | $901.9M | $737.7M | ||
| Q2 24 | $904.5M | $744.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSETD
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $-1.8M | ||
| Q3 25 | $108.5M | $16.8M | ||
| Q2 25 | $4.4M | $24.8M | ||
| Q1 25 | $-53.4M | $10.2M | ||
| Q4 24 | $19.4M | $11.6M | ||
| Q3 24 | $34.1M | $15.1M | ||
| Q2 24 | $-8.3M | $26.2M |
自由现金流APLSETD
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $-4.7M | ||
| Q3 25 | $108.3M | $14.4M | ||
| Q2 25 | $4.4M | $22.9M | ||
| Q1 25 | $-53.4M | $8.2M | ||
| Q4 24 | $19.3M | $7.8M | ||
| Q3 24 | — | $11.5M | ||
| Q2 24 | $-8.4M | $24.2M |
自由现金流率APLSETD
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -3.2% | ||
| Q3 25 | 23.6% | 9.8% | ||
| Q2 25 | 2.5% | 14.3% | ||
| Q1 25 | -32.0% | 5.7% | ||
| Q4 24 | 9.1% | 5.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | -4.2% | 14.3% |
资本支出强度APLSETD
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.9% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 1.2% |
现金转化率APLSETD
| Q1 26 | — | — | ||
| Q4 25 | — | -0.16× | ||
| Q3 25 | 0.50× | 1.61× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.06× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 1.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ETD
暂无分部数据
